22.8 C
New York
Sunday, June 14, 2026

Tag: Securities and Exchange Commission

Robo.ai Subsidiary Neurovia AI Newly Appointed Chief Operating Officer, Rashed Aleghfeli, to Participate at the 2026 UAE Data Center Infrastructure & Cloud Summit

ABU DHABI, UAE, June 10, 2026 /PRNewswire/ -- Robo.ai Inc. (NASDAQ: AIIO) today announced the appointment of Emirati executive Mr. Rashed Aleghfeli as Chief...

Vision Marine Technologies Extends Nextfour Agreement Through 2029 to Strengthen E-Motion™ Connected Platform Capabilities

Technology / E-Motion™ Platform IntelligenceVision Marine is extending a key display supply and integration relationship through 2029, supporting the connected digital interface of its...

Solidion Technology Withdraws Previously Filed Registration Statement

The withdrawal does not reflect any change in the Company's business outlook, operating strategy, or confidence in the value of its assetsDALLAS, June 10,...

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.

ING rolls out global subscription banking model

ING rolls out global subscription banking model

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

Hut 8 Closes $4.25 Billion of Investment-Grade Senior Secured Notes for Beacon Point Data Center Project

Hut 8's second investment-grade data center construction bond — fully amortizing, non-recourse, and non-dilutive — rated Baa2 and priced 20 basis points inside the...

RMG ML Sports Holdings Announces the Pricing of $200 Million Initial Public Offering

Incline Village, NV, June 09, 2026 (GLOBE NEWSWIRE) -- RMG ML Sports Holdings (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chief Executive Officer, James Carpenter, and President and Chief Financial Officer, Douglas Horlick, today announced the pricing of its initial public offering of 20,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right to receive one-eighth (1/8) of one Class A ordinary share upon the consummation of the Company’s initial business combination. The units are expected to trade on the Global Market tier of the Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “SHOTU” beginning June 10, 2026. Once the securities comprising the units begin separate trading, the ordinary shares and the rights are expected to be traded on Nasdaq under the symbols “SHOT” and “SHOTR,” respectively.

Maui Land & Pineapple Company, Inc. Appoints a Chief Investment Officer

KAPALUA, Hawai‘i, June 09, 2026 (GLOBE NEWSWIRE) -- Maui Land & Pineapple Company, Inc. (NYSE: MLP) today announced the appointment of Ryan Panopio as the Company’s Chief Investment Officer effective June 3, 2026.

Ramaco Resources to Participate in StoneX Fourth Annual Natural Resources Summit

LEXINGTON, Ky., June 9, 2026 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB) ("Ramaco" or the "Company") today announced that Jeremy Sussman, Chief Financial...

Devon Energy Provides Updated 2026 Outlook

HOUSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Devon Energy Corp. (NYSE: DVN) today provided an updated outlook for the combined company following the recent completion of its transformative merger with Coterra Energy. Supplemental guidance tables for the combined entity are included below and a presentation is available on the company’s website at www.devonenergy.com.

Orchid Island Capital Announces June 2026 Monthly Dividend and May 31, 2026 RMBS Portfolio Characteristics

VERO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of June 2026. The dividend of $0.10 per share will be paid July 30, 2026 to holders of record of the Company’s common stock on June 30, 2026, with an ex-dividend date of June 30, 2026. The Company plans on announcing its next common stock dividend on July 8, 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSecurities and Exchange Commission